TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03883958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: ESPB will be performed in sitting or lateral decubitus position. The target vertebral level will be correspond to the approximate mid-point of the extent of fractured ribs. The tip of the transverse process of the target vertebra will be identified using the high-frequency linear placed in cephalocaudal orientation about 3 cm to the spinous process. The skin and subcutaneous tissue will be infiltrated with 2-3 ml of 2% lignocaine. With the transducer fixed over the targeted TP, a 22-gauge 88-mm needle (Spinocan, B. Braun, Germany) will be advanced in-plane to the ultrasound beam in a cephalo-caudal direction to contact the TP. Correct needle tip position will be confirmed by doing alternating aspiration to confirm lack of inadvertent vascular puncture with injection of 1-2 ml of saline and visualizing linear fluid spread deep to erector spinae muscle, separating it from the TP. A bolus dose (2ml/segment) of plain bupivacaine 0.5% plus 4mg of Dexamethasone will be injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block
Description: TPVB will be performed at a spinal level midway between the uppermost and the lowest fractured rib with the patient in sitting or lateral decubitus position (with patients lying on their unaffected side). The ultrasound-guided technique will be used. A high-frequency linear transducer will be used to confirm the levels of the fractured ribs. The most cephalad and most caudad fractured ribs will be identified first. The fractured rib in the middle will be then identified, and the rib will be then traced back medially. After skin and subcutaneous tissue infiltration with 2-3 ml of 2% lignocaine, a 22-gauge 88-mm needle (Spinocan, B. Braun, Germany) will be inserted in a lateral-to-medial direction until the needle tip entered the paravertebral space. 1-2 ml of Saline will be injected into the paravertebral space while observing the pleura being moved deeply. A bolus dose (2ml/segment) of plain bupivacaine 0.5% plus 4mg of Dexamethasone will be injected.
Study: NCT01514279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthyCHANGE
Description: Cognitive behavioral strategies to address diet, physical activity, sedentary behavior and sleep for children.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls.
Study: NCT00519987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ketamine
Description: intranasal ketamine
Study: NCT02719197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-083
Description: Hard gelatin capsules for oral administration formulated at a strengths of 1, 10 and 100 mg
Study: NCT04061473

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 2 placebo tablets.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
Study: NCT02886065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hiltonol
Description: Intramuscular injection of Hiltonol (1 mg) administered Biweekly at the time of PVX-410 administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hiltonol
Description: Intramuscular injection of Hiltonol (1 mg) administered Biweekly at the time of PVX-410 administration
Study: NCT01514279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SystemCHANGE
Description: Intervention (based on systems improvement and choice architecture theories) System improvement and choice architecture theories seek to teach a set of skills using family self-designed experiments to redesign daily routines regarding eating, activity and sleep.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls.
Study: NCT02719197

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching AC-083 capsules
Study: NCT03896269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study: NCT04396860

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo contrast-enhanced brain MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo contrast-enhanced brain MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT01812239

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Progesterone gel.
Description: Daily administration of Vaginal Progesterone gel in pregnant women with twins between the 20th week of pregnancy and the 34th week of pregnancy.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: fetal fibronectin swab.
Description: Collection of quantatative fetal fibronectin swab one week after randomization into the trial for both arms. Randomziation occurs between 20 weeks - 24 weeks of gestation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fetal fibronectin swab.
Description: Collection of quantatative fetal fibronectin swab one week after randomization into the trial for both arms. Randomziation occurs between 20 weeks - 24 weeks of gestation.
Study: NCT04396860

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NovoTTF-100A Device
Description: Wear Optune device
Study: NCT03832725

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Protein (HP) weight loss diet
Description: Newly diagnosed Type 2 Diabetic (NT2DM) subjects will be placed on a HP diet for 6 months with all food provided for weight loss and remission of NT2DM.~Intervention with the HP diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment
Study: NCT01812239

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: weekly vaginal administration of the placebo gel from randomization until 34 weeks of gestation.
Study: NCT03543735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wisepill+SMS
Description: This will include: 1) an in-person Wisepill orientation session to introduce the pillbox and generate relapse prevention messages that can be later delivered during non-adherent windows; 2) use of the Wisepill device during the intensive treatment program and after discharge; and 3) three forms of tailored SMS messages paired with Wisepill device use: a) supportive messages with medication compliance, b) reminder messages for early non-adherence (e.g., 1 hour late) and c) relapse-prevention messages after longer periods of non-adherence (e.g., several hours).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wisepill-only
Description: This will include: 1) an in-person Wisepill orientation session to introduce the pillbox; 2) use of the Wisepill during the intensive treatment program and after discharge.
Study: NCT04396860

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Given PO
Study: NCT02886065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citarinostat
Description: Citarinostat (180 mg) administered orally once daily on days 1-21 every 28 day cycle.
Study: NCT03381651

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation
Description: 50.4Gy/28F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation
Description: 41.4Gy/23F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
Study: NCT03832725

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High carbohydrate (HC) weight loss diet
Description: Newly diagnosed Type 2 Diabetic (NT2DM) subjects will be placed on a HC diet for 6 months with all food provided for weight loss and remission of NT2DM.~Intervention with the HP diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment
Study: NCT03760081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1650
Description: Participants received ASP1650 dose level 1 or dose level 2 as intravenous infusion, Q2W starting on C1D1 for up to a maximum of 12 cycles or until study discontinuation criterion was met, whichever occurred earlier. Duration of each treatment cycle was 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1650
Description: Participants received ASP1650 dose level 1 or dose level 2 as intravenous infusion, Q2W starting on C1D1 for up to a maximum of 12 cycles or until study discontinuation criterion was met, whichever occurred earlier. Duration of each treatment cycle was 14 days.
Study: NCT01917227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Study: NCT02986139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Commercial Formulation Etanercept
Description: Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the commercial formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Commercial Formulation Etanercept
Description: Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the commercial formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Formulation Etanercept
Description: Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the new formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Formulation Etanercept
Description: Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the new formulation.
Study: NCT02344849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell
Description: Patients will receive single injection of Cellgram-ED( 30,000,000 mesenchymal stem cell) intracavernously.
Study: NCT01216020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: * Cetuximab is given according to the standard mode of administration: loading dose : 400 mg/m2 one week before the start of radiotherapy (week -1), followed by a weekly dose of 250 mg/m2 during the weeks of the treatment with radiotherapy.~* Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin (associated to radiotherapy)
Description: * CDDP dose: 40 mg/mq in a single weekly 1-hour infusion preceded by adequate hydration, diuretics e antiemetic premedication.~* Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed.
Study: NCT03199196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity Tracker
Description: Group 1 - Intervention: Participants given an accelerometer at each visit. Participant wears the accelerometer for 7 days.~Group 2 - Newsletters: After completing the 16 week visit, participant given an activity tracker.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone Application
Description: Group 1 - Intervention: Participant given smartphone application baseline visit to track physical activity, connect with participant's partner to share information about participant's physical activity, and provide support to partner to be more physically active.~Group 2 - Newsletters: After completing the 16 week visit, participant given instruction in the use of a smartphone application.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete questionnaires about feelings, moods, motivation for physical activity, any social support received from others, the neighborhood participant lives in, and other physical activity-related topics. Questionnaires completed 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.The questionnaires should take about 45 minutes to complete.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Participants complete questionnaires about feelings, moods, motivation for physical activity, any social support received from others, the neighborhood participant lives in, and other physical activity-related topics. Questionnaires completed 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.The questionnaires should take about 45 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Participants invited to take part in a final focus group. Focus group takes place sometime after the 16-week visit. Focus groups/interviews are audio recorded.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Focus Group
Description: Participants invited to take part in a final focus group. Focus group takes place sometime after the 16-week visit. Focus groups/interviews are audio recorded.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Newsletters
Description: Participant emailed electronic newsletters to read that may help participant be more physically active.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Electronic Newsletters
Description: Participant emailed electronic newsletters to read that may help participant be more physically active.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Research staff provides telephone counseling to participant and partner biweekly during weeks 1-8 (weeks 1, 3, 5, and 7), and monthly during weeks 9-16 (weeks 11 and 15).
Study: NCT02662582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reldesemtiv
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reldesemtiv
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet
Study: NCT02886065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citarinostat
Description: Citarinostat (180 mg) administered orally once daily on days 1-21 every 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide (25 mg) administered orally once daily on days 1-21 every 28 day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVX-410
Description: PVX-410 Biweekly (0.8 mg) via subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVX-410
Description: PVX-410 Biweekly (0.8 mg) via subcutaneous injection
Study: NCT04025281

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extra Virgin Olive Oil
Description: Participants will consume a meal prepared with 50 mL extra virgin olive oil. The meals will be prepared and provided to the study participants in the cafeteria of Griffin Hospital, where the Prevention Research Center is located. With the exception of the type of olive oil used in the meals, the meal plan will be comparable in all the intervention phases for the same individual.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refined Olive Oil
Description: Participants will consume a meal prepared with 50 mL refined olive oil in the cafeteria of Griffin Hospital. With the exception of the olive oil used, the meal plan will be comparable in each the intervention phases for the same individual.
Study: NCT04135352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg of pembrolizumab
Description: Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg of pembrolizumab
Description: Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg of pembrolizumab
Description: Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg of pembrolizumab
Description: Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg of pembrolizumab
Description: Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg of pembrolizumab
Description: Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg of pembrolizumab
Description: Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.
Study: NCT03997474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATL001
Description: ATL001 infusion
Study: NCT04135352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg of pembrolizumab
Description: Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg of pembrolizumab
Description: Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V938
Description: Participants receive V938 intratumorally in cycles 1-7. Each cycle is 21 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V938
Description: Participants receive V938 intratumorally in cycles 1-7. Each cycle is 21 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V938
Description: Participants receive V938 intratumorally in cycles 1-7. Each cycle is 21 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V938
Description: Participants receive V938 intratumorally in cycles 1-7. Each cycle is 21 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V938
Description: Participants receive V938 intratumorally in cycles 1-7. Each cycle is 21 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V938
Description: Participants receive V938 intratumorally in cycles 1-7. Each cycle is 21 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V938
Description: Participants receive V938 intratumorally in cycles 1-7. Each cycle is 21 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V938
Description: Participants receive V938 intratumorally in cycles 1-7. Each cycle is 21 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V938
Description: Participants receive V938 intratumorally in cycles 1-7. Each cycle is 21 days.
Study: NCT03997474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATL001
Description: ATL001 infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATL001
Description: ATL001 infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Checkpoint Inhibitor
Description: Nivolumab
Study: NCT02867358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KT07 Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KT07 Capsule

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04381871

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acacia Senegal
Description: Oral Digestion of Gum Arabic to be consumed early morning on daily basis for 4weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pectin
Description: Oral Digestion of Pectin to be consumed early morning on daily basis for 12 weeks
Study: NCT01506349

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gluten
Description: 4 grams of gluten.
Study: NCT03004495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5259 and CHF6001
Description: b.i.d. for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF5259 + placebo
Description: b.i.d. for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF6001 + placebo
Description: b.i.d. for 14 days
Study: NCT05027893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg Oral Tablet
Description: All used film-coated tablets (400 mg moxifloxacin) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefixime 400 mg Oral Tablet
Description: All used film-coated tablets (400 mg cefixime) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All used film-coated placebo-tablets were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
Study: NCT03004495

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: b.i.d. for 14 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: b.i.d. for 14 days